- Home
- FGEN vs DXR Comparison
FGEN vs DXR Comparison
Compare FGEN & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- DXR
- Stock Information
- Founded
- FGEN 1993
- DXR 1970
- Country
- FGEN United States
- DXR United States
- Employees
- FGEN N/A
- DXR N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- DXR Medical/Dental Instruments
- Sector
- FGEN Health Care
- DXR Health Care
- Exchange
- FGEN Nasdaq
- DXR Nasdaq
- Market Cap
- FGEN 33.5M
- DXR 36.4M
- IPO Year
- FGEN 2014
- DXR N/A
- Fundamental
- Price
- FGEN $5.30
- DXR $9.63
- Analyst Decision
- FGEN Strong Buy
- DXR Strong Buy
- Analyst Count
- FGEN 1
- DXR 1
- Target Price
- FGEN $250.00
- DXR $25.00
- AVG Volume (30 Days)
- FGEN 53.3K
- DXR 5.1K
- Earning Date
- FGEN 08-05-2025
- DXR 01-01-0001
- Dividend Yield
- FGEN N/A
- DXR N/A
- EPS Growth
- FGEN N/A
- DXR 86.16
- EPS
- FGEN N/A
- DXR 0.11
- Revenue
- FGEN $6,996,000.00
- DXR $119,714.00
- Revenue This Year
- FGEN N/A
- DXR N/A
- Revenue Next Year
- FGEN N/A
- DXR N/A
- P/E Ratio
- FGEN N/A
- DXR $86.39
- Revenue Growth
- FGEN N/A
- DXR N/A
- 52 Week Low
- FGEN $4.50
- DXR $6.55
- 52 Week High
- FGEN $38.25
- DXR $10.00
- Technical
- Relative Strength Index (RSI)
- FGEN 31.98
- DXR 69.88
- Support Level
- FGEN $5.22
- DXR $8.68
- Resistance Level
- FGEN $5.85
- DXR $9.03
- Average True Range (ATR)
- FGEN 0.59
- DXR 0.47
- MACD
- FGEN -0.17
- DXR 0.03
- Stochastic Oscillator
- FGEN 4.72
- DXR 90.38
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.